Arovella Therapeutics (ALA) EGM 2025 summary
Event summary combining transcript, slides, and related documents.
EGM 2025 summary
27 Nov, 2025Opening remarks and agenda
Meeting opened at 11:00 A.M. with a quorum present and proper constitution confirmed.
Directors and Company Secretary introduced; apology noted for one absent director.
Meeting held virtually, enabling live participation, Q&A, and voting.
Specific resolutions to be voted on
Resolution One: Ratification of the issue of placement shares from March 2025 placement.
Resolution Two: Ratification of placement options from March 2025 placement.
Proxy results for both resolutions displayed and determined by poll.
Q&A with stakeholders
Shareholders could submit questions via the online platform, with instructions provided.
Questions addressed included webcast availability and future meeting formats.
Confirmation given that webcasts are posted on the investor website.
Explanation provided for virtual format due to director locations; future meetings planned as hybrid or in-person.
Latest events from Arovella Therapeutics
- Losses increased and revenue declined, but clinical and cash milestones were achieved.ALA
H1 20268 Mar 2026 - IND filed for ALA-101, Phase 1 trial set for 2026, $19.4M cash, and robust pipeline expansion.ALA
Q2 2026 TU23 Jan 2026 - Clinical and strategic milestones achieved as CAR-iNKT pipeline advances toward trials.ALA
AGM 202529 Dec 2025 - Strong cash position and clinical progress with ALA-101 and ALA-105 programs, plus new US patent.ALA
Q1 2026 TU7 Dec 2025 - $23.5M cash and $15M raise secure phase I trial and pipeline progress for 2025 milestones.ALA
Q3 202528 Nov 2025 - Off-the-shelf iNKT cell therapies advance to clinical trials, targeting blood and solid cancers.ALA
Investor Presentation18 Nov 2025 - Off-the-shelf iNKT cell therapies advance toward clinical trials, targeting key cancer indications.ALA
Investor Presentation23 Sep 2025 - Loss narrowed and cash reserves strengthened as lead iNKT cell therapy advances to clinical trials.ALA
H2 202531 Aug 2025 - $20.9M cash enables clinical trial progress and pipeline expansion, with 7.5 quarters funding secured.ALA
Q4 2025 TU28 Jul 2025